David Sulman

David Sulman

Auto-generated profile, based on publicly available information

David Sulman

ACTION Study Group, Sorbonne Université, Inserm, UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, 75013, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Heart
Verified
Journal Article
Closed access
PDF file
MZMichel Zeitouni
Michel Zeitouni
DSDavid Sulman
David Sulman
JSJohanne Silvain
Johanne Silvain
MKMathieu Kerneis
Mathieu Kerneis
PGPaul Guedeney
Paul Guedeney
GMGilles Montalescot
Gilles Montalescot
Objective To determine if the changes in the European Society Cardiology/European Atherosclerotic Society (ESC/EAS) guidelines improved the identification for primary prevention therapy in young adults at risk of a premature myocardial infarction. Methods Patients admitted for a first ST-segment elevation myocardial infarction (STEMI) in the ePARIS registry (n=2757) between 2010 and 2018 were classified by age: 65 years old. Using Systematic Coronary Risk Estimation 2, we evaluated whether patients would have been detected and treated with primary prevention statins before their first STEMI based on the 2021 EAS/ESC guidelines versus 2019 and 2016 guidelines. Eligibility for intensive proprotein convertase subtilisin/kexin type 9 (PCSK9i) in secondary prevention was also assessed. Results Following 2021 ESC guidelines, 62.5% of individuals aged 65 years old (19% and 72%), p<0.01. After their first STEMI, 25% of patients 65 years. Conclusions The 2021 ESC guidelines allowed a much better detection of young individuals before their first STEMI than prior ESC guidelines. In secondary prevention, most of young individuals did not reach low-density lipoprotein cholesterol levels recommended, but only one quarter would be eligible for PCSK9i.

3 September 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
DSDavid Sulman
David Sulman
ADArthur Darmon
Arthur Darmon
GDGregory Ducrocq
Gregory Ducrocq
A 62-year-old male was admitted with pulmonary oedema. He had a previous history of anterior myocardial infarction in 1997 treated with intravenous fibrinolysis complicated by tamponade requiring surgical drainage. He developed left ventricular (LV) dysfunction [left ventricular ejection fraction (LVEF) 25%] and LV pseudoaneurysm. Despite oral anticoagulation with Vitamin K Antagonist (VKA) with International Normalized Ratio (INR) in the therapeutic range, and low-dose aspirin, he suffered three transient ischaemic attacks in 2009, 2010 again, and 2012 and a stroke in 2017. The LVEF was stable throughout the years, with the first documentation of LV thrombus in 2016. He had not previously shown heart failure symptoms and had no symptoms whilst taking bisoprolol and ramipril. However, the patient elected not to take Bisoprolol for 6 months. On admission, blood pressure was 135/76 mmHg, heart rate 130/min, and he required oxygen at 2 L/min with SpO2 at 97%. Physical examination showed crackles in both lung fields without any other signs of congestion. Biology sample was unremarkable and N-terminal prohormone of brain natriuretic peptide was 659 ng/mL. The electrocardiogram (Panel A) revealed Q waves in anterior and anterolateral leads. Chest X-ray (Panel B) showed a large heavily calcified LV pseudoaneurysm. LVEF was less than 10% on echocardiography with only a preserved contractility in the basal segments of the LV. Cardiac computed tomography (CT) (Panels C and D) and magnetic resonance imaging (MRI) (Panels E and F) showed a severely depressed LVEF (8%) with a 90 mm apical LV pseudoaneurysm without sign of rupture filled with a 12 mm lining thrombus. The LV end-diastolic volume dimension was of 233.86 mL/m2 (N = 77.0 mL/m2). The cardiac index was estimated at 1.56 L/min/m2. Clinical condition improved under intravenous diuretics. He was discharged home under sacubitril/valsartan (24/26 mg, b.i.d.) after Ramipril wash-out, furosemide 40 mg, atorvastatin 40 mg, and increased dose of VKA for a target INR of 2.5–3.5 with the withdrawal of aspirin, without switching for direct oral anticoagulants due to unclear benefit compared to VKA in this situation. Surgical correction of LV pseudoaneurysm was not performed due to very high operative risk with few clinical benefits expected. We recommended the implantation of an internal cardiac defibrillator before discharge; however, the patient refused this intervention despite being provided with information regarding the high risk of ventricular arrhythmias, but however accepted the prescription of a LifeVest (Zoll Medical). He was included in the heart transplant program, with a complete pre-transplant assessment scheduled for a week after discharge. This case allows apprehending the natural course of untreated LV pseudoaneurysm: a low risk of rupture after the acute phase, a calcific remodelling, and a high risk of thrombo-embolic events.

9 February 2026 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
AEAnthony Elhadad
Anthony Elhadad
OZOmar El Zouhayri
Omar El Zouhayri
JSJohanne Silvain
Johanne Silvain
MKMathieu Kerneis
Mathieu Kerneis
DSDavid Sulman
David Sulman
MZMichel Zeitouni
Michel Zeitouni

1 April 2025 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Open access
AEAnthony Elhadad
Anthony Elhadad
DSDavid Sulman
David Sulman
NPNiki Procopi
Niki Procopi
PDPerrine Devos
Perrine Devos
FBFrederic Beaupré
Frederic Beaupré
MZMichel Zeitouni
Michel Zeitouni
Background and aims: There are currently no data regarding pre-treatment with P2Y12 inhibitors in patients with acute myocardial infarction complicated with cardiogenic shock (AMI-CS). This study investigates the effectiveness and safety of pre-treatment with P2Y12 inhibitors in patients with AMI-CS. Methods and results: Using the ACTION-SHOCK cohort, we included consecutive patients hospitalized between 2012 and 2023 with AMI-CS admitted for coronary angiography within 24 h of admission. Pretreatment was defined by the administration before angiography of an oral loading dose of a P2Y12 inhibitor. We evaluated the association between pretreatment and either major adverse cardiovascular events (MACE) or major bleeding at 30 days after admission, using an inverse probability weighting (IPW) approach. MACE was defined by the composite of all-cause death, ischaemic stroke, myocardial infarction, or stent thrombosis. Major bleeding was defined by Bleeding Academic Research Consortium grade 3, 4, or 5. Among the 421 patients with AMI-CS admitted to the catheterization laboratory within 24 h of admission, 224 (53.2%) patients received pre-treatment with a P2Y12 inhibitor. No association between pre-treatment with P2Y12 inhibitor and MACE at 30 days was found [42.1% vs. 38.8%—IPW hazard ratio (wHR): 1.11, 95% CI: 0.82–1.50]. Pre-treatment was associated with an increased risk of major bleeding (42.2% vs. 32.3%—wHR: 1.48, 95% CI: 1.05–2.08). The effect of pre-treatment on MACE or major bleeding at 30 days is consistent across STEMI/NSTEMI patients. Conclusion: In patients with AMI-CS, pretreatment with a P2Y12 inhibitor oral load was associated with an increased risk of major bleeding without benefit on MACE.

2 July 2025 in European Heart Journal - Imaging Methods and Practice
Verified
Journal Article
Open access
DSDavid Sulman
David Sulman
SMStéphane Manzo-Silberman
Stéphane Manzo-Silberman
The 2019 ESC guidelines redefined stable coronary artery disease as chronic coronary syndrome (CCS), highlighting the dynamic nature of this disease. This condition is characterized by the gradual accumulation of atherosclerotic plaques in the epicardial coronary arteries. CCS can result in myocardial ischaemia due to supply–demand mismatch, often triggered by physical or emotional stress. The clinical course may be abruptly interrupted by plaque rupture or erosion, leading to acute coronary syndromes. Revolutionary advances in non-invasive imaging have transformed the chronic coronary syndrome diagnosis algorithm and management. Coronary computed tomography angiography provides detailed anatomical insights, identifying high-risk plaques with features like low attenuation and positive remodelling, as evidenced by SCOT-HEART, which reported reduced coronary events (HR: 0.59, P = 0.004). Stress echocardiography may detect ischaemia-induced wall motion abnormalities (sensitivity, 85–95%), while cardiovascular magnetic resonance is paramount in functional assessment, offering 81–86% sensitivity/specificity and detecting microvascular dysfunction via perfusion and late gadolinium enhancement. Nuclear imaging (SPECT/PET) enhances ischaemia detection, with PET’s myocardial flow reserve improving prognostic accuracy (sensitivity 90%, specificity 88%). AI-driven innovations, such as CT-derived fractional flow reserve, automate plaque quantification and may reduce in the future unnecessary invasive angiographies by 19–25% (P = 0.01), while dynamic CT myocardial perfusion integrates anatomical and hemodynamic data, boosting diagnostic accuracy (87%). These advancements enable precise risk stratification and a personalized multimodal imaging approach, based on pre-test likelihood. It also increases the risk of unsustainable costs for society, repeated radiation exposure throughout a patient's life, and raises the question of actual limited benefits from revascularization in low-risk patients.

6 October 2026 in Archives of Cardiovascular Diseases
Verified
Journal Article
Open access
NPNiki Procopi
Niki Procopi
PGPaul Guedeney
Paul Guedeney
AFArnaud Ferrante
Arnaud Ferrante
MZMichel Zeitouni
Michel Zeitouni
MKMathieu Kerneis
Mathieu Kerneis
GHGérard Helft
Gérard Helft
Heart transplantation (HT) recipients undergo repeated coronary angiographies to screen for coronary allograft vasculopathy, which increases exposure to non-radial vascular access and potential related complications. To describe the incidence and determinants of non-radial vascular approach among HT recipients in a large HT centre. Consecutive HT recipients undergoing coronary angiography between October 2020 and March 2024 in the largest European HT centre were included, and all their previous coronary angiographies performed after HT were retrospectively reviewed. Determinants of non-radial vascular approach were assessed using multivariable logistic regression analyses, which included the individual mean number of coronary angiographies per year after HT to account for disparities in follow-up. A total of 429 patients (21.4% female, median [interquartile range] age at HT 50 [38-58] years) underwent a total of 1927 procedures, with a median number of 3 (1-7) coronary angiographies per patient performed over a median duration of 6.7 (1.3-12.9) years. The cumulative rate of non-radial vascular approach at 10 years was 35.5% (95% confidence interval: 29.9-41.1%). Independent determinants of non-radial vascular approach were HT for ischaemic heart disease (adjusted odds ratio [aOR]: 2.78, 95% confidence interval [95% CI]: 1.69-4.54), multiple HT (aOR: 5.71, 95% CI: 1.42-23.01), female sex (aOR: 2.22, 95% CI: 1.18-4.16) and chronic dialysis after HT (aOR: 3.19, 95% CI: 1.09-9.28), but the number of procedures was not. Severe vascular complications were rare and not significantly different between vascular accesses. In this high-volume centre, non-radial vascular approach was used in approximately one third of HT recipients during their follow-up, with multiple reasons, albeit not including the overall number of procedures performed.